- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jill Jarecki Discusses the Current Pipeline for SMA Therapies
Combination treatments may be the future for treating patients with spinal muscular atrophy (SMA) at all stages and ages, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA and research director of TREAT-NMD Neuromuscular Network.
Combination treatments may be the future for treating patients with spinal muscular atrophy (SMA) at all stages and ages, explained Jill Jarecki, PhD, chief scientific officer at Cure SMA and research director of TREAT-NMD Neuromuscular Network.
Transcript
What else is in the pipeline for SMA and how do those therapies differ from what is already approved?
So, at CureSMA, we're working to fund a number of drugs in the SMA drug pipeline and the reason for that is that there has been dramatic changes with the FDA approved drugs in our presymptomatic in our younger patient population. And we also get clinically meaningful, but more modest gains, in our older patients who are chronically living with SMA.
So, we believe that we need a cocktail approach to achieve maximally effective benefit in all stages and ages of SMA. And this likely means combination therapies, and combination therapies that target either muscle function or motor neuron function. Muscle drugs are the furthest along with this sort of combination, or cocktail, approach. And we have a drug in clinical trials with Scholar Rock that helps with the muscle side of things.
And in our pipeline, we have many early stage drugs that focus on more diverse approaches, and that's where CureSMA is currently directing our funding, to help identify novel drug approaches for SMA that can be layered on with our approved SMN [survival of the motor neuron] upregulating drugs.
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
